# A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

> **NCT02880371** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 82 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ARRY-382
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02880371
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-01
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-10-24
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880371, "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02880371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*